PLI scheme for bulk drugs and medical devices receives 243 applications

  • Industry News
  • Dec 02,20
Production Linked Incentive (PLI) Scheme for bulk drugs and medical devices, which closed on 30 November 2020, received 215 and 28 applications from manufacturers of bulk drugs and medical devices respectively
PLI scheme for bulk drugs and medical devices receives 243 applications

New Delhi

Production Linked Incentive (PLI) Scheme for bulk drugs and medical devices, approved in March 2020 and notified in July 2020 with a total financial outlay of Rs 34.20 billion, has evoked a very positive response with 243 applications received from pharmaceutical and medical devices companies.  

Under the PLI Scheme for bulk drugs, 215 applications were made by 83 pharmaceutical manufacturers. Similarly, 28 applications made by 23 manufacturers have been received under the PLI Scheme for medical devices. The closing date of applications was November 30, 2020. IFCI Ltd is the Project Management Agency (PMA) for implementation of both the schemes.

The appraisal process of the applications has commenced from December 1, 2020 and a maximum of 136 applications under the PLI scheme for bulk drugs and a maximum of 28 applications under the PLI scheme for medical devices will be approved. The time duration for giving approval to the applicants is 90 days under the PLI scheme for bulk drugs and 60 days under the PLI scheme for medical devices. However, best efforts will be done by the PMA and the Department of Pharmaceuticals to give early approvals to the participants under the scheme.

Looking at the increasing imperative of drug security, support to domestic production capability in bulk drugs would ensure higher resilience of the Indian pharmaceutical industry to external shocks. The PLI scheme for medical devices will help meet the objective of product diversification and production of innovative and high value medical devices in India. These initiatives have the potential to contribute significantly to achieving higher objective of affordable healthcare in the country and globally on a sustained basis.

The PLI Schemes for bulk drugs and medical devices - along with electronics manufacturing industry - was approved by the Government on March 20, 2020. For bulk drugs & medical devices, the initial guidelines for implementation of both the schemes which were initially issued on July 27, 2020 were amended based on the feedback received from the industry. These revised guidelines were issued on October 29, 2020. Both the schemes have shown a very encouraging response from the pharmaceutical as well as the medical device industry.

In October 2020, Ministry of Electronics and Information and Technology (MeitY) approved 16 eligible applicants under the PLI Scheme for electronics manufacturing. 

In November 2020, as part of Aatmanirbhar Bharat 3.0 initiative, the Government of India has extended the PLI Scheme to 10 new sectors with additional financial outlay of Rs 1460 billion over a 5-year period to enhance India’s manufacturing capabilities and enhancing exports. The new sectors that are included for the scheme are advance chemistry cell (ACC) battery, electronic/technology products, automobiles & auto components, pharmaceutical drugs, telecom & networking products, textile products (man-made fibres and technical textiles), food products, high efficiency solar PV modules, white goods (ACs & LED), and speciality steel.

The Indian pharmaceutical industry is the third largest in the world by volume and 14th largest in terms of value. It contributes 3.5 per cent of the total drugs and medicines exported globally. India possesses the complete ecosystem for development and manufacturing of pharmaceuticals and a robust ecosystem of allied industries. Under PLI scheme 2.0, Rs 150 billion has been allocated for pharmaceutical industry to incentivise the global and domestic players to engage in high value production.

Related Stories

Electrical & Electronics
Tendulkar backed RRP Electronics to invest Rs 5,000 cr in Semiconductor Plant

Tendulkar backed RRP Electronics to invest Rs 5,000 cr in Semiconductor Plant

Describing it as Maharashtra's pioneering semiconductor facility, Chodankar highlighted Tendulkar's role as a "strategic investor" in the company

Read more
Electrical & Electronics
Tata Electronics Chairman urges doubling India's electronic manufacturing

Tata Electronics Chairman urges doubling India's electronic manufacturing

Agrawala further said the government should continue to work with the sense of urgency they have shown so far and ensure that the enabling infrastructure for manufacturing is in place

Read more
Electrical & Electronics
Supply Chain, Testing Hurdles hinder India's electrical growth: IEEMA President

Supply Chain, Testing Hurdles hinder India's electrical growth: IEEMA President

Arsiwala also emphasized the need for clearer state-level energy policies, particularly in emerging sectors like e-mobility, renewables, and green hydrogen

Read more

Related Products

Programmable Controllers - Pcd-33a Series

CHEMICAL PROCESS, FOOD/PHARMA EQUIPMENT & ANALYTICAL INSTRUMENTS

Pro-Med Instruments (P) Ltd offers a wide range of programmable controllers - PCD-33A Series.


Read more

Request a Quote

Gasket Graphite Powder

CHEMICAL PROCESS, FOOD/PHARMA EQUIPMENT & ANALYTICAL INSTRUMENTS

Arihant Packing & Gasket Company offers a wide range of gasket graphite powder. 


Read more

Request a Quote

Asahi Kasei expands 3D printing filament sales in North America

CHEMICAL PROCESS, FOOD/PHARMA EQUIPMENT & ANALYTICAL INSTRUMENTS

Asahi Kasei, a leading resin and compounding technology provider, has initiated the sales of 3D printing (3DP) filaments in North America through Asahi Kasei Plastics North America (APNA). The soft la Read more

Request a Quote

Hi There!

Now get regular updates from IPF Magazine on WhatsApp!

Click on link below, message us with a simple hi, and SAVE our number

You will have subscribed to our Industrial News on Whatsapp! Enjoy

+91 84228 74016

Reach out to us

Call us at +91 8108603000 or

Schedule a Call Back